A validated risk stratification tool can help identify dermatomyositis patients most likely to have an underlying cancer. A Mount Sinai study of 413 patients confirmed that those in the high-risk group had the highest rate of paraneoplastic disease (8.8%), compared to 5.1% in intermediate- and 2.5% in low-risk groups. Being 40 or older at diagnosis was the strongest predictor of cancer association.
A new study out of Mount Sinai Health System has validated international cancer screening guidelines for patients with dermatomyositis — an inflammatory skin and muscle condition that can sometimes signal an underlying malignancy. Researchers reviewed records of 413 adult patients seen between 2019 and 2024, stratifying them into high-, intermediate-, and low-risk groups based on established criteria from the International Myositis Assessment and Clinical Studies Group (IMACS).
The results confirmed the tool's real-world utility: 6.5% of patients were diagnosed with paraneoplastic dermatomyositis (cancer occurring within 3 years of dermatomyositis onset), and the high-risk group captured the lion's share of those cases. Notably, age 40 or older at diagnosis was the single strongest predictor of cancer association.
By the Numbers:
Why it matters: These findings reinforce the value of structured, risk-based cancer screening in newly diagnosed dermatomyositis patients — and highlight that intermediate-risk patients may need prolonged monitoring, since most of their cancers surface well after initial diagnosis.
